Pharmacyte Biotech Inc (OTCMKTS:PMCB) reported that Dr. Matthias Lohr, the Chairman of its Scientific Advisory Board, and Dr. Manuel Hidalgo have joined several other oncologists from the U.K., Spain, Italy, Belgium and Germany in co-authoring a key review article on pancreatic cancer. This article, which was recently published in the scientific journal Pancreatology, focuses on the issues related with the treatment of Pancreatic Cancer and the future directions for achieving better outcomes.
Pharmacyte reported that the article focuses on pancreatic ductal adenocarcinoma which accounts for more than 90% of pancreatic cancers. The severity and statistics of PDAC are highlighted and its development is detailed. Of prime importance to company is the evaluation of current treatment alternatives and the unmet medical need for locally advanced and operable PDAC.
Relypsa Inc (NASDAQ:RLYP) reported that it has finalized a two-year detailing deal with Sanofi SA (ADR)(NYSE:SNY) for Patiromer FOS. It is Relypsa’s investigational drug that is currently under assessment for the cure of hyperkalemia with the U.S. FDA, with a PDUFA action date in October 2015.
Relypsa plans to commercialize Patiromer FOS after the U.S.FDA approval with its specialty sales force and dedicated commercial team of nearly 120 sales representatives. The team will focus mainly on outreach to cardiologists, hospitals and nephrologists. As per the finalized deal, Sanofi’s nephrology team will complement Relypsa’s measures by detailing Patiromer FOS in the U.S. for a two-year period. During this period, Sanofi will get a service fee and incentive payments.
After registering strong gains on Thursday, the stock price of Pfizer Inc. (NYSE:PFE) is moving lower on the chart. It posted gains after the company reported the initiation of a global phase 3 study on its breast cancer medication, Ibrance. The study will be conducted with an objective of evaluating the impact of Ibrance when complemented with standard treatment on disease-free survival rate.